• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Advanced NanoTherapies wins FDA breakthrough nod for drug-coated balloon

September 19, 2022 By Sean Whooley

Advanced NanoTherapies Sirplux Duo
[Image from Advanced NanoTherapies]
Advanced NanoTherapies announced today that it received FDA breakthrough device designation for its SirPlux Duo drug-coated balloon (DCB).

Los Gatos, California-based Advanced NanoTherapies received the breakthrough nod for the use of the DCB in treating coronary artery disease in vessels less than 3.0mm. The regulatory win comes weeks after two previous breakthrough designations. SirPlux Duo already has a breakthrough designation for coronary in-stent restenosis (ISR) and peripheral below-the-knee (BTK) lesions.

SirPlux Duo combines sirolimus and paclitaxel to create a next-generation front-line therapy. It is designed to provide stent-like patency and restenosis prevention while leaving no implant behind. The DCB delivers low-dose, long-term release of both compounds to inhibit cell growth. This results in maximum potency exceeding any other DCB or drug-eluting stent, according to Advanced NanoTherapies.

“Despite decades of advances in drug-eluting stents, treating small coronary vessels continues to be challenging due to the unacceptable incidence of restenosis and target lesion failure,” said Dr. Rishi Puri coronary and structural heart interventional cardiologist in the Tomsich Family Department of Cardiovascular Medicine at Cleveland Clinic and co-principal investigator of the company’s ADVANCE-DCB clinical trial. “Advanced NanoTherapies is championing a novel stent-free option to address this clinical gap. I look forward to seeing how this technology can advance the field of coronary interventions by improving long-term clinical outcomes and preventing the need for repeat revascularizations.”

More about Advanced NanoTherapies and the SirPlux Duo

SirPlux Duo features a proprietary nanoparticle drug encapsulation and delivery platform. It provides safe and sustained bioavailability of sirolimus and paclitaxel in tissue for long-term outcomes.

Advanced NanoTherapies raised $7.2 million to support the technology earlier this year. The company has brought in $12.5 million in total since 2020.

“Our third breakthrough designation emphasizes the urgent need for new coronary and peripheral therapies with a leave nothing behind approach,” said Marwan Berrada-Sounni, co-founder and CEO of Advanced NanoTherapies. “We appreciate the collaborative approach the FDA has taken to reviewing our technology and the novelty of combining two synergistic drugs. Over the coming months, we will build on this positive momentum as we generate first-in-human clinical data using the SirPlux Duo DCB.”

Filed Under: Cardiovascular, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Regulatory/Compliance Tagged With: Advanced NanoTherapies, FDA

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS